Serum amyloid A protein in clinical cancer diagnosis

Pathology and Oncology Research

Volumn 18, Issue 2, 2012, Pages 117-121

  Liu, Chibo ^a  

^a TAIZHOU MUNICIPAL HOSPITAL   (China)

Author keywords

Cancer diagnosis; Inflammation; Proteomics; SAA; SELDI TOF MS; Serum amyloid A

Indexed keywords

SERUM AMYLOID A; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; UPREGULATION;

HUMANS; NEOPLASMS; SERUM AMYLOID A PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84863456621     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9459-7     Document Type: Review

References (76)

1. Cecconi D, Palmieri M, Donadelli M (2011) Proteomics in pancreatic cancer research. Proteomics 11:816-828
2. van Gorp T, Cadron I, Vergote I (2011) The utility of proteomics in gynecologic cancers. Curr Opin Obstet Gynecol 23:3-7
3. Hamrita B, Nasr HB, Chahed K, Chouchane L (2011) Proteomics approaches: new technologies and clinical applications in breast carcinomas. Gulf J Oncolog 1:36-44
4. Gemoll T, Roblick UJ, Auer G, Jornvall H, Habermann JK (2010) SELDI-TOF serum proteomics and colorectal cancer: a current overview. Arch Physiol Biochem 116:188-196
5. Matta A, Ralhan R, Desouza LV, Siu KW (2010) Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery. Mass Spectrom Rev 29:945-961
6. Plymoth A, Hainaut P (2011) Proteomics beyond proteomics: toward clinical applications. Curr Opin Oncol 23:77-82
7. Sipe J (1999) Revised nomenclature for serum amyloid A (SAA). Nomenclature Committee of the International Society of Amyloidosis. Part 2. Amyloid 6:67-70
8. Malle E, de Beer FC (1996) Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 26:427-435
9. Yamada T (2006) Serum amyloid A (SAA)-pathogenicity and implication of appearance in plasma. Rinsho Byori 54:509-512
10. Barcelo JR, Munoz A, MANE JM et al (2003) Amyloidosis and lung cancer. Clin Lung Canc 4:249-251, discussion 252
11. Comenzo RL (2006) Amyloidosis. Curr Treat Options Oncol 7:225-236
12. Kwon AH, Tsuji K, Yamada H, Okazaki K, Sakaida N (2007) Amyloidosis of the gallbladder mimicking gallbladder cancer. J Gastroenterol 42:261-264
13. Al Mofleh IA (2008) Severe acute pancreatitis: pathogenetic aspects and prognostic factors. World J Gastroenterol 14:675-684
14. Hilliquin P (1995) Biological markers in inflammatory rheumatic diseases. Cell Mol Biol (Noisy-le-grand) 41:993-1006
15. Rau BM (2007) Predicting severity of acute pancreatitis. Curr Gastroenterol Rep 9:107-115
16. Rau B, Schilling MK, Beger HG (2004) Laboratory markers of severe acute pancreatitis. Dig Dis 22:247-257
17. D'Eril GM, Anesi A, Maggiore M, Leoni V (2001) Biological variation of serum amyloid A in healthy subjects. Clin Chem 47:1498-1499
18. Hijmans W, Sipe JD (1979) Levels of the serum amyloid A protein (SAA) in normal persons of different age groups. Clin Exp Immunol 35:96-100
19. Biran H, Friedman N, Neumann L, Pras M, Shainkin-Kestenbaum R (1986) Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 39:794-797
20. Chan DC, Chen CJ, Chu HC et al (2007) Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol 14:84-93
21. O'Hanlon DM, Lynch J, Cormican M, Given HF (2002) The acute phase response in breast carcinoma. Anticancer Res 22:1289-1293
22. Raynes JG, Cooper EH (1983) Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and nonmalignant disease. J Clin Pathol 36:798-803
23. Preciado-Patt L, Levartowsky D, Prass M, Hershkoviz R, Lider O, Fridkin M (1994) Inhibition of cell adhesion to glycoproteins of the extracellular matrix by peptides corresponding to serum amyloid A. Toward understanding the physiological role of an enigmatic protein. Eur J Biochem 223:35-42
24. Urieli-Shoval S, Shubinsky G, Linke RP, Fridkin M, Tabi I, Matzner Y (2002) Adhesion of human platelets to serum amyloid A. Blood 99:1224-1229
25. Preciado-Patt L, Hershkoviz R, Fridkin M, Lider O (1996) Serum amyloid A binds specific extracellular matrix glycoproteins and induces the adhesion of resting CD4+ T cells. J Immunol 156:1189-1195
26. Brown EJ (1986) The role of extracellular matrix proteins in the control of phagocytosis. J Leukoc Biol 39:579-591
27. Chen ST, Pan TL, Juan HF, Chen TY, Lin YS, Huang CM (2008) Breast tumor microenvironment: proteomics highlights the treatments targeting secretome. J Proteome Res 7:1379-1387
28. Garlanda C, Maina V, Martinez de la Torre Y, Nebuloni M, Locati M (2008) Inflammatory reaction and implantation: the new entries PTX3 and D6. Placenta 29(Suppl B):129-134
29. Mas VR, Fisher RA, Archer KJ, Maluf DG (2009) Proteomics and liver fibrosis: identifying markers of fibrogenesis. Expert Rev Proteomics 6:421-431
30. Uhlar CM, Whitehead AS (1999) Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265:501-523
31. Agaram N, Shia J, Klimstra DS et al (2005) Globular hepatic amyloid: a diagnostic peculiarity that bears clinical significance. Hum Pathol 36:845-849
32. Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M (2009) Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist. Eur Cytokine Netw 20:225-234
33. Bareggi SR, Cornelli U (2010) Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders. CNS Neurosci Ther
34. Cho WC (2007) Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Canc 6:1
35. Cho WC, Yip TT, Yip C et al (2004) Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Canc Res 10:43-52
36. Cho WC, Yip TT, Cheng WW, Au JS (2010) Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br J Canc 102:1731-1735
37. Cocco E, Bellone S, El-Sahwi K et al (2009) Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. Br J Canc 101:335-341
38. Cocco E, Bellone S, El-Sahwi K et al (2010) Serum amyloid A: a novel biomarker for endometrial cancer. Cancer 116:843-851
39. Cohen AD, Comenzo RL (2010) Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Am Soc Hematol Educ Program 2010:287-294
40. Comenzo RL (2007) Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis. Contrib Nephrol 153:195-210
41. Cremona M, Calabro E, Randi G et al (2010) Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk. Cancer 116:1326-1335
42. Dai S, Wang X, Liu L et al (2007) Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum. Sci China C Life Sci 50:305-311
43. Junker K, Von Eggeling F, Muller J, Steiner T, Schubert J (2006) Identification of biomarkers and therapeutic targets for renal cell cancer using ProteinChip technology. Urologe A 45:305-306, 308, 310-12 passim
44. Klock G, Baiersdorfer M, Koch-Brandt C (2009) Chapter 7: Cell protective functions of secretory Clusterin (sCLU). Adv Canc Res 104:115-138
45. Le Y, Yang Y, Cui Y et al (2002) Receptors for chemotactic formyl peptides as pharmacological targets. Int Immunopharmacol 2:1-13
46. Le L, Chi K, Tyldesley S et al (2005) Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 51:695-707
47. Liu DH, Wang XM, Zhang LJ et al (2007) Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer. Biomed Environ Sci 20:33-40
48. Malle E, Sodin-Semrl S, Kovacevic A (2009) Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 66:9-26
49. Marshall FF (2005) Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. J Urol 173:1919-1920
50. Maru Y (2009) Logical structures extracted from metastasis experiments. Canc Sci 100:2006-2013
51. Meethal SV, Smith MA, Bowen RL, Atwood CS (2005) The gonadotropin connection in Alzheimer's disease. Endocrine 26:317-326
52. Merchant S, Sun J, Korbelik M (2007) Dying cells program their expedient disposal: serum amyloid P component upregulation in vivo and in vitro induced by photodynamic therapy of cancer. Photochem Photobiol Sci 6:1284-1289
53. Michaeli A, Finci-Yeheskel Z, Dishon S, Linke RP, Levin M, Urieli-Shoval S (2008) Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer. Biochem Biophys Res Commun 368:368-373
54. Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB et al (2005) Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 5:3790-3797
55. Moshkovskii SA, Vlasova MA, Pyatnitskiy MA et al (2007) Acute phase serum amyloid A in ovarian cancer as an important component of proteome diagnostic profiling. Proteomics Clin Appl 1:107-117
56. Okutani D (2006) The role of long pentraxin 3, a new inflammatory mediator in inflammatory responses. Nihon Rinsho Meneki Gakkai Kaishi 29:107-113
57. Pierce BL, Neuhouser ML, Wener MH et al (2009) Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Canc Res Treat 114:155-167
58. Sasazuki S, Inoue M, Sawada N et al (2010) Plasma levels of Creactive protein and serum amyloid A and gastric cancer in a nested case-control study: Japan Public Health Center-based prospective study. Carcinogenesis 31:712-718
59. Segal BH, Kwon-Chung J, Walsh TJ et al (2006) Immunotherapy for fungal infections. Clin Infect Dis 42:507-515
60. Tolson J, Bogumil R, Brunst E et al (2004) Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 84:845-856
61. Uys A, Rapoport BL, Fickl H, Meyer PW, Anderson R (2007) Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care (Engl) 16:475-483
62. Vermaat JS, van der Tweel I, Mehra N et al (2010) Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Ann Oncol 21:1472-1481
63. Wall JS, Paulus MJ, Gleason S, Gregor J, Solomon A, Kennel SJ (2006) Micro-imaging of amyloid in mice. Meth Enzymol 412:161-182
64. Wang CS, Sun CF (2009) C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J 32:471-482
65. Wang XD, Lu DH, Song H et al (2009) Value of combining 64 multi-slice spiral computer tomography and serum amyloid A protein in surgical decision-making in rectal cancer. Zhonghua Wai Ke Za Zhi 47:1693-1697
66. Wood SL, Rogers M, Cairns DA et al (2010) Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Canc 103:101-111
67. Yokoi K, Shih LC, Kobayashi R et al (2005) Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. Int J Oncol 27:1361-1369
68. Hutchens TW, Yip TT (1993) New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom 7:576-580
69. Zhou M, Veenstra T (2008) Mass spectrometry: m/z 1983-2008. Biotechniques 44(667-8):670
70. Clarke CH, Buckley JA, Fung ET (2005) SELDI-TOF-MS proteomics of breast cancer. Clin Chem Lab Med 43:1314-1320
71. Engwegen JY, Gast MC, Schellens JH, Beijnen JH (2006) Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 27:251-259
72. Fung ET, Enderwick C (2002) ProteinChip clinical proteomics: computational challenges and solutions. Biotechniques Suppl 34-8:40-41
73. Garrisi VM, Abbate I, Quaranta M, Mangia A, Tommasi S, Paradiso A (2008) SELDI-TOF serum proteomics and breast cancer: which perspective? Expert Rev Proteomics 5:779-785
74. Kislinger T, Humeny A, Pischetsrieder M (2004) Analysis of protein glycation products by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Curr Med Chem 11:2185-2193
75. Naishiro Y, Suzuki C, Kimura M et al (2007) Plasma analysis of rheumatoid arthritis by SELDI. Nihon Rinsho Meneki Gakkai Kaishi 30:145-150
76. Wiltfang J, Lewczuk P, Riederer P et al (2005) Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatr 6:69-84